Trial Profile

First in human clinical trial assessing iTOL 102

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ITOL 102 (Primary)
Indications Type 1 diabetes mellitus
Focus Adverse reactions; First in man

Most Recent Events

30 Oct 2025 According to a NewcelX media release, Kadimastem has merged with NLS Pharmaceutics Ltd to form NewcelX.
18 Mar 2025 According to an iTolerance, Inc media release, company received US $1.0 million grant from BIRD foundation, the funding will be used to support clinical application of iTOL-102.
10 Mar 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com